Present risk of anthracycline or radiation-induced cardiac sequelae following therapy of malignancies in children and adolescents

Klinische Padiatrie

Volumn 221, Issue 3, 2009, Pages 162-166

  Chen, C ^a   Heusch, A ^a   Donner, B ^a   Janssen G ^a   Gobel U ^a   Schmidt, K G ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Anthracycline; Cardiomyopathy; Chemotherapy; Childhood; Radiation

Indexed keywords

ANTHRACYCLINE; DOXORUBICIN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE HEART FAILURE; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHILD; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; EWING SARCOMA; FEMALE; HEART ARRHYTHMIA; HEART LEFT VENTRICLE FAILURE; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEPHROBLASTOMA; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; OSTEOSARCOMA; PRACTICE GUIDELINE; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SCHOOL CHILD; SCREENING TEST; SUPRAVENTRICULAR TACHYCARDIA; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; DRUG EFFECT; HEART; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; MASS SCREENING; MULTIMODALITY CANCER THERAPY; NEOPLASM; RADIATION DOSE; RADIATION EXPOSURE; RADIATION INJURY;

ADOLESCENT; ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARRHYTHMIAS, CARDIAC; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; HEART; HEART FAILURE; HUMANS; MALE; MASS SCREENING; NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; TACHYCARDIA, SUPRAVENTRICULAR; VENTRICULAR DYSFUNCTION, LEFT;

EID: 68949170698     PISSN: 03008630     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0029-120722     Document Type: Article

References (31)

1. Adams MJ, Lipsitz SR, Colan SD et al. Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol 2004 22 3139-3148
2. Adams MJ, Lipshultz SE. Pathophysiology of anthracycline- and radiation-associated cardiomyopathies: Implications for screening and prevention. Pediatr Blood Cancer 2005 44 600-606
3. Ballestrero A, Ferrando F, Garuti A et al. High-dose mitoxantrone with peripheral blood progenitor cell rescue: toxicity, pharmacokinetics and implications for dosage and schedule. Br J Cancer 1997 76 797-804
4. Bredin F, Liska J, Franco-Cereceda A. Changes in natriuretic peptides following passive containment surgery in heart failure patients with dilated cardiomyopathy. Interact Cardiovasc Thorac Surg 2009 8 191-194
5. Bölling T, Schuck A, Pape H et al. Register for the evaluation of side effects after radiation in childhood and adolescence - first results. Klin Pädiatr 2007 219 139-145
6. Bu?Lock FA, Mott MG, Oakhill A et al. Early identification of anthracycline cardiomyopathy: possibilities and implications. Arch Dis Child 1996 75 416-422
7. Calaminus G, Weinspach S, Teske C et al. Quality of survival in childhood and adolescents after treatment for childhood cancer: The influence of reported late effects on health related quality of life. Klin Pädiatr 2007 219 152-157
8. Catalano O, Antonaci S, Moro G et al. Contrast-enhanced cardiac magnetic resonance in apatient with chemotoxic cardiomyopathy. J Cardiovasc Med 2007 8 214-215
9. Clark SJ, Pippon M, Hemsworth S et al. Cardiac troponin T following anthracycline chemotherapy in children and adolescents. J Chemother 2007 19 332-334
10. Clerico M, Rivoiro C, Contessa G et al. The therapy of multiple sclerosis with immune- modulating or immunosuppressive drug: A critical evaluation based upon evidence based parameters and published systematic reviews. Neurologie 2003 18 318-323
11. Creutzig U, Diekamp S, Zimmermann M et al. Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AML. Pediatr Blood Cancer 2007 48 651-662
12. Debling D, Spix C, Blettner M et al. The cohort of long-term survivors at the German Childhood Cancer Registry. Klin Pädiatr 2008 220 371-377
13. Elbl L, Hrstkova H, Chaloupka V. The late consequences of anthracycline treatment on left ventricular function after treatment for childhood cancer. Eur J Pediatr 2003 162 690-696
14. Geidel S, Garn M, Gravinghoff L et al. Cardiomyopathy after treatment for osteosarcoma: a contribution to cardiotoxicity of adriamycin. Klin Pädiatr 1991 203 257-261
15. Godoy LY, Fukushige J, Igarashi H et al. Anthracycline-induced cardiotoxicity in children with malignancies. Acta Paediatr Jpn 1997 39 188-193
16. Grenier MA, Lipshultz SE. Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol 1998 25 (Suppl 10) 72-85
17. Hauser M, Gibson BS, Wilson N. Diagnosis of anthracycline-induced late cardiomyopathy by exercise-spiroergometry and stress-echocardiograpy. Eur J Pediatr 2001 160 607-610
18. Iarussi D, Indolfi P, Galderisi M et al. Cardiac toxicity after anthracycline chemotherapy in childhood. Herz 2000 25 676-688
19. Kampmann C. Normal values of M mode echocardiographic measurements of more than 2000 healthy infants and children in central Europe. Heart 2000 83 667-672
20. Koch H, Schmitz L, Brockmeier K et al. Langzeituntersuchung zur anthracyclininduzierten Kardiomyopathie bei Kindern und Jugendlichen. Klin Pädiatr 1991 203 262-267
21. Lipshultz SE. Exposure to anthracyclines during childhood causes cardiac injury. Semin Oncol 2006 33 (Suppl 8) 8-14
22. Marx M, Langer T, Graf N et al. Multicenter analysis of anthracycline-induced cardiotoxicity in children following treatment according to the nephroblastoma studies SIOP No.9/GPOH and SIOP 93-01/GPOH. Med Pediatr Oncol 2002 39 18-24
23. Nagy AC, Tolnay E, Nagykalnai T et al. Cardiotoxicity of anthracycline in young breast cancer female patients: the possibility of detection of early cardiotoxicity by TDI. Neoplasma 2006 53 511-517
24. Paulides M, Kremers A, Stöhr W et al. Prospective longitudinal evaluation of doxorubicine-induced cardiomyopathy in sarcoma patients: a report of the late effects surveillance system (LESS). Pediatr Blood Cancer 2006 46 489-495
25. Polena S, Shikara M, Naik S et al. Troponin I as a marker of doxorubicin induced cardiotoxicity. Proc West Pharmacol Soc 2005 48 142-144
26. Semenov DE, Lushnikova EL, Nepomnyashchikh LM. Anthracycline-induced cardiomyopathy is manifested in decreased protein synthesis, impaired intracellular regeneration, and non-necrotic death of cardiomyocytes. Bull Exp Biol Med 2001 131 505-510
27. Speyer J, Wasserheit C. Strategies for reduction of anthracycline cardiac toxicity. Semin Oncol 1998 25 525-537
28. Ward KM, Binns H, Chin C et al. Pediatric heart transplantation for anthracycline cardiomyopathy: cancer recurrence is rare. J Heart Lung Transplant 2004 23 1040-1045
29. Watts RG. Severe and fatal anthracycline cardiotoxicity at cumulative dose below 400mg/m2: evidence for enhanced toxicity with multiagent chemotherapy. Am J Hematol. 1991 36 217-218
30. Weiss MA, Drullinsky P, Maslak P et al. A phase I trial of a single high dose of idarubicin combined with high-dose cytarabine as induction therapy in relapsed or refractory adult patients with acute lymphoblastic leukemia. Leukemia 1998 12 865-868
31. Zuppinger C, Timolati F, Suter TM. Pathophysiology and diagnosis of cancer drug induced cardiomyopathy. Cardiovasc Toxicol 2007 7 61-66